International production facilities in eight countries.
Affiliates or offices in 75 countries.
|Approximately 41,600 employees (March 2016).
|Approximately 42% of employees are located in Denmark (17,888) and 58% in the rest of the world (USA: 6,384, Region China: 4,390, International Operations: 7,431, Europe: 4,483, Pacific: 1,481).
|20% within research and development
32% in production and production administration
36% in international sales and marketing
12% in administration
We have five product areas:
Growth hormone therapy
Hormone replacement therapy
According to applicable law, only health care professionals are allowed to access product information on our site. Please find the information under Health Care Professionals.
For patient and disease information, including pens and needles, please look under Patients.
27,212 million Danish kroner Q1 2016
Sales by business segment
Diabetes and obesity care 21,031 million Danish kroner
Biopharmaceuticals 6,181 million Danish kroner
Sales by region
USA: 13,730 million Danish kroner
Europe: 5,016 million Danish kroner
International Operations: 3,516 million Danish kroner
Region China: 2,875 million Danish kroner
Pacific: 2,075 million Danish kroner
Novo Nordisk A/S
CVR nr. 24 25 67 90
Download annual reports, interim reports,
investor presentations and much more in our download centre
Learn more about Novo Nordisk shares.
Facts about Novo Nordisk products